Scynexis SCYX
NASDAQ SCYX
$4.91 -0.24 (-4.66%)
At close: Sep 9, 2026 · 4:00 PM EDT

Scynexis (SCYX) Non-Current Deffered Revenue (2013 - 2025)

Scynexis' (SCYX) quarterly Non-Current Deffered Revenue came in at $807000.0 in Q3 2025, down 37.92% on a YoY basis from $1.3 million in Q3 2024, and up 56.7% quarter-over-quarter from $515000.0 in Q2 2025.

Analysis

Scynexis (SCYX) Non-Current Deffered Revenue (2013 - 2025) Analysis & Trends

Scynexis (SCYX) has reported Non-Current Deffered Revenue for 9 consecutive years, with $807000.0 the latest figure, recorded in Q3 2025.

  • For the quarter ending Q3 2025, Non-Current Deffered Revenue fell 37.92% year-over-year to $807000.0; the trailing twelve-month figure through Sep 2025 stood at $807000.0 (down 37.92% YoY), and the FY2024 full-year result was $1.3 million, down 52.33% from the prior year.
  • Non-Current Deffered Revenue advanced to $807000.0 in Q3 2025 per SCYX's latest filing, from $515000.0 in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $2.7 million in Q4 2023 and bottomed at $515000.0 in Q2 2025.
  • Historically, Non-Current Deffered Revenue has averaged $1.5 million across 3 years, with a median of $1.3 million in 2024.
  • The sharpest annual moves came in 2024 and 2025: Non-Current Deffered Revenue jumped 59.39% in 2024, then tumbled 71.66% in 2025.
  • Over 3 years, Non-Current Deffered Revenue stood at $2.7 million in 2023, then tumbled by 52.33% to $1.3 million in 2024, then sank by 37.92% to $807000.0 in 2025.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $807000.0, $515000.0, and $1.3 million for Q3 2025, Q2 2025, and Q1 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Amgen 211.73 Bn 197.74 Bn 7.24 Bn -
2 Gilead Sciences 180.92 Bn 177.74 Bn 6.22 Bn -
3 Vertex Pharmaceuticals 132.16 Bn 124.30 Bn 2.84 Bn -
4 Regeneron Pharmaceuticals 82.89 Bn 74.90 Bn 3.93 Bn 220.40 Mn
5 Argenx Se 61.41 Bn 56.23 Bn 1.37 Bn -
6 Moderna 53.99 Bn 48.85 Bn 52.00 Mn 147.00 Mn
7 Alnylam Pharmaceuticals 34.48 Bn 31.18 Bn 992.69 Mn -
8 Biogen 31.15 Bn 29.86 Bn 1.96 Bn -
9 Roivant Sciences 30.05 Bn 30.05 Bn 1.16 Mn -
10 Scynexis 58.41 Mn -56.29 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2025 807,000.00
Jun 30, 2025 515,000.00
Mar 31, 2025 1.30 Mn
Dec 31, 2024 1.30 Mn
Sep 30, 2024 1.30 Mn
Jun 30, 2024 1.82 Mn
Mar 31, 2024 2.11 Mn
Dec 31, 2023 2.73 Mn
Sep 30, 2023 1.65 Mn
Jun 30, 2023 1.14 Mn
Mar 31, 2018 57,000.00
Dec 31, 2017 121,000.00
Sep 30, 2017 185,000.00
Jun 30, 2017 249,000.00
Mar 31, 2017 314,000.00
Dec 31, 2016 378,000.00
Sep 30, 2016 442,000.00
Jun 30, 2016 507,000.00
Mar 31, 2016 571,000.00
Dec 31, 2015 635,000.00